Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

The Hatch-Waxman Act created a careful balance in pharmaceutical patent law. Generic drug companies can sell the same chemical compound as a brand-name drug, but they must carve out any patented uses from their labels. If the brand holds a patent on using Drug X for heart disease, the generic can sell Drug X for a different condition, and its label must say nothing about the patented heart disease use.

Hikma followed this framework. Its label carved out the patented use entirely. A doctor looking at Hikma's label would find no mention of reducing cardiac risk in patients with moderate triglycerides. The question is whether marketing materials outside the label can undo that careful carve-out.

Amarin's theory rests on Hikma's press release. By calling its product a "generic version" of Vascepa and citing Vascepa's sales data, Hikma arguably signaled to the market that its drug does the same thing Vascepa does, including the patented use. Doctors who already know about Vascepa's cardiac benefits might prescribe Hikma's generic for that purpose, even though Hikma's label does not mention it.

Hikma's defense is that calling something a "generic version" is a factual statement -- it is the same chemical -- and citing public sales data is not an instruction to use the drug for any particular purpose. Induced infringement requires active encouragement to infringe, not merely making a product available that someone might misuse. If a press release that states publicly available facts is enough to trigger inducement liability, the entire generic drug carve-out system is at risk.

This case matters for every generic drug that shares a compound with a patented brand-name medication. The Hatch-Waxman carve-out system depends on generic companies being able to sell approved drugs without worrying that any reference to the brand will be treated as inducing infringement of the brand's patents.

If the Court rules that a press release calling a drug a "generic version" is enough to plead inducement, generic companies will face litigation risk every time they market their products in relation to the brand-name equivalent. That would chill generic competition and undermine the purpose of the Hatch-Waxman Act, which was to make cheaper drugs available to patients. If the Court rules that label carve-outs are sufficient and marketing statements about public facts are not inducement, it protects the generic drug market but potentially limits brand-name patent holders' ability to enforce method patents.